Compare Ishares Msci Brazil ETF (EWZ) vs Moderna, Inc. (MRNA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ishares Msci Brazil ETF vs Moderna, Inc. — how do they compare? Ishares Msci Brazil ETF trades at $43.54 (market cap $11.30B), while Moderna, Inc. trades at $225 (market cap $78.65B). The key difference: Moderna, Inc. is far larger — about 7× Ishares Msci Brazil ETF's market cap, and Ishares Msci Brazil ETF is more actively traded (44,036,597 versus 37,373,437). Which is the better fit depends on your goals — on Pluang, investors hold Ishares Msci Brazil ETF for 50 Days and Moderna, Inc. for 59 Days on average.
| EWZ | MRNA | |
|---|---|---|
Market Cap | $11.30B | $78.65B |
Volume | 44,036,597 | 37,373,437 |
Sector | Broad Market / Factor | Health |
52-Week High | $43.00 | $203.46 |
52-Week Low | $28.79 | $22.36 |
Typical Hold Time | 50 Days | 59 Days |
Enterprise Value | — | $74.80B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EWZ, the iShares MSCI Brazil ETF, is trading at $43.54, up 2.76% today, with strong bullish momentum from moving averages but overbought RSI signals. The ETF is positioned as a diversification play against U.S. tech concentration, benefiting from Brazil's commodity exposure and election-driven optimism. Recent unusual options activity and institutional buying reflect heightened investor interest ahead of October's presidential election.
The outlook hinges on Brazil's election outcome and commodity trends, offering asymmetric upside via call spreads. Risks include political volatility, U.S. tariff impacts, and competition from lower-fee Brazil ETFs like FLBR. Wall Street sentiment is cautiously optimistic, with the trade acting as a hedge against AI-driven U.S. market risks.
Moderna (MRNA) trades at $197.00, up 0.26% on the day, with technical indicators showing a bullish trend and strong momentum. The stock has rallied over 500% in 2026, driven by positive clinical updates for its cancer vaccine pipeline and inclusion in the Nasdaq-100 index effective October 9, 2026. However, fundamentals remain challenging with revenue declining from $18.9B in 2022 to $1.9B in 2025 and negative net income margins exceeding 140%.
While technical momentum and pipeline optimism support near-term upside, valuation appears stretched with P/S of 35.08 and negative profitability metrics. Key risks include execution on non-COVID products, competitive pressure, and sustainability of recent gains. Analyst consensus is cautious with only 28% buy ratings and $115.70 price target suggesting significant downside from current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Ishares Msci Brazil ETF
EWZ is a country-specific ETF that tracks the Brazilian equity market. It provides exposure to large and mid-sized companies in Brazil, with a heavy focus on financials and materials, including major names like Nu Holdings, Vale, and Itaú Unibanco.
Read more on EWZ →About Moderna, Inc.
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →
